Final Program

146 MONDAY • MAY 16
624 Neonatal SMAD3 Promoter Hypermethylation Predicts Asthma
in Children of Asthmatic Mothers from Three Birth Cohorts/
A. DeVries, G. Wlasiuk, S.J. Miller, A. Bosco, D.A. Stern, I.C.
Lohman, J. Rothers, A.C. Jones, J. Nicodemus-Johnson, J.A.
Curtin, A. Simpson, A. Custovic, D.J. Jackson, J.E. Gern, R.F.
Lemanske, Jr., S. Guerra, A.L. Wright, C. Ober, M. Halonen, D.
Vercelli, Tucson, AZ p.A2938
625 Large-Scale Genome-Wide Association Study of Asthma in the
Kaiser Permanente Northern California’s Genetic
Epidemiology Research on Adult Health and Aging
(KPNC-GERA) Cohort/A. Dahlin, J. Ziniti, C. Iribarren, M. Lu, K.
Tantisira, S.T. Weiss, A.C. Wu, Boston, MA, p.A7938
B22
POSTER DISCUSSION SESSION
BURDEN OF PULMONARY AND CRITICAL CARE
MEDICINE: COST AND UTILIZATION
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 304 (South Building, Esplanade Level)
Poster Viewing 9:00-9:45
Discussion 9:45-11:00
Chairing: S.S. Carson, MD, Chapel Hill, NC
J.K. Gerald, MD, PhD, Tucson, AZ
M.P. Kerlin, MD, Philadelphia, PA
201 Healthcare Use and Costs Among Patients with Non-Cystic
Fibrosis Bronchiectasis in the US/C.M. Blanchette, J.M. Noone,
G. Stone, E. Zacherle, M.C. Runken, R. Howden, Charlotte, NC,
p.A2939
202 Inpatient Trend for Adult Cystic Fibrosis in the United States
from 1998-2013: A 15 Year Analysis/A. Agrawal, I.A. Lalani, S.S.
Alagusundaramoorthy, D. Du, Long Branch, NJ, p.A2940
203 Trends in Inpatient Admissions of Pulmonary Hypertension in
the United States from 2000-2013/A. Agrawal, D. Mehta, I.A.
Lalani, A. Agarwal, A. Talwar, Long Branch, NJ, p.A2941
204 Excess Economic Burden in Asthma Patients and the Impact
of Comorbidities/W. Chen, L.D. Lynd, M.J. Fitzgerald, C. Marra,
R. Balshaw, T. To, H. Tavakoli, M. Sadatsafavi, Vancouver,
Canada, p.A2942
205 Occurrence of Severe Asthma Events and Exacerbations by
Level of Controller Therapy in Patients with Asthma in the
United States/M. DePietro, E. Durden, K.M. Fox, M. Brouillette,
J.R. Davis, M. Bonafede, Wilmington, DE, p.A2943
206 What Is the Cost of Asthma in the States?/T. Nurmagambetov,
O.A. Khavjou, L. Murphy, D. Orenstein, Atlanta, GA, p.A2944
207 Prevalence and Features of Asthma. Results of a
Population-Based Nationwide Survey in Argentina/A.J. Videla,
S. Arias, J.C. Bossio, C.A. Calabrese, G. Armando, H. Neffen,
Buenos Aires, Argentina, p.A2945
208 Medical Service Utilization Among Australian Older Women
with Asthma/P. Eftekhari, P.M. Forder, J.E. Byles, Callaghan,
Australia, p.A2946
209 The Economic Burden of Asthma, Allergic Rhinitis, COPD and
Rhinosinusitis in Korea/K.-H. Yoo, H.-R. Ahn, J.-K. Park, J.-W.
Kim, G.-H. Nam, S.-K. Hong, M.-J. Kim, A. Ghoshal, A.R.B.A.
Muttalif, H.C. Lin, S. Thanaviratananich, S. Bagga, R. Faruqi, S.
Baidya, C. Taylor, D.Y. Wang, S.-H. Cho, Seoul, Korea, Republic
of, p.A2947
210 The Association of Depression with Emergency Department
Use in Chronic Obstructive Pulmonary Disease/H. Weerahandi,
J.P. Wisnivesky, M.S. Kale, M. Martynenko, M. Wolf, A. Federman,
New York, NY, p.A2948
211 The Burden of Illness Related to COPD Exacerbations in
Quebec, Canada/R. Tavares, T. Dang-Tan, S. Zhang, M. Stutz, A.
Ismaila, J. Vaillancourt, D. Corriveau, R.H. Stanford, X. Lin, G.
Nadeau, A. Simidchiev, D. Parsons, J.S. Sampalis, Mississauga,
Canada, p.A2949
212 Economic Burden of Chronic Obstructive Pulmonary Disease
(COPD) in Patients with and Without Co-Morbid Cardiovascular
Disease (CVD) in the United States/R.H. Stanford, M.R. Bogart,
Research Triangle Park, NC, p.A2950
213 Economic Surveillance for Chronic Obstructive Pulmonary
Disease (COPD) in Alberta, Canada/A. Waye, P. Jacobs, M.
Stickland, M.B. Ospina, I. Mayers, Edmonton, Canada, p.A2951
214 Sarcoidosis-Associated Hospitalizations in the United States,
2002-2012/A.B. Wills, J.R. Fontana, C.A. Steiner, H.C. Ackerman,
A.P. Ruhl, K.N. Olivier, D.R. Prevots, Bethesda, MD, p.A2952
215 Cost Consequences of Initial Combination Treatment of PAH
with Ambrisentan and Tadalafil/R.J. Oudiz, S.C. Mathai, R.J.
White, M. Jacobsen, D. Weycker, C.D. Burger, Torrance, CA,
p.A2953
216 Healthcare Utilization and Direct Costs Among Pulmonary
Arterial Hypertension Patients Before and After Treatment
Initiation in the United States/C.D. Burger, B. Ozbay, E. Riehle,
L.B. Montejano, R.J. White, Jacksonville, FL, p.A2954
217 The Incidence of ICU Admissions in a Privately Insured
Population Across the United States/G.E. Weissman, N.B.
Gabler, M.P. Kerlin, S.D. Halpern, Philadelphia, PA, p.A2955
218 Effect of Hospital Characteristics and Quality Metrics on ICU
Utilization Practices: A Multi-State Cross-Sectional
Analysis/K.S. Mathews, J. Zhou, M. Mazumdar, G.N. Stock, C.M.
McDermott, New York, NY, p.A2956
219 Male Predominance in Admission to Intensive Care Units (ICU)
Disappears After Surviving One ICU Admission/C.D. Ramsey,
A. Hill, P. Dodek, R. Fowler, J. Kozak, H. Wong, R. Fransoo, M.
Doupe, M. Yogendran, A. Garland, Winnipeg, Canada, p.A2957
220 Identifying the Organizational and Process Factors Driving
Treatment Intensity at the End of Life Within and Upstream of
the Intensive Care Unit: A Positive Deviance Study/C. Lin, J.
Jopling, K. Vranas, M. Ramsey, M. Simons, D. Zionts, H. Chiou, T.
Wagner, A. Milstein, Stanford, CA, p.A2958
ATS 2016 • San Francisco